Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0105 | 0.2914 | 0.5 |
Plasmodium vivax | S-adenosylmethionine decarboxylase-ornithine decarboxylase, putative | 0.0122 | 0.3743 | 1 |
Plasmodium falciparum | S-adenosylmethionine decarboxylase/ornithine decarboxylase | 0.0122 | 0.3743 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0105 | 0.2914 | 0.5 |
Entamoeba histolytica | ornithine decarboxylase, putative | 0.0122 | 0.3743 | 0.5 |
Echinococcus granulosus | arachidonate 5 lipoxygenase | 0.012 | 0.3665 | 1 |
Trypanosoma brucei | ornithine decarboxylase | 0.0122 | 0.3743 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0105 | 0.2914 | 0.7283 |
Giardia lamblia | Ornithine decarboxylase | 0.0122 | 0.3743 | 1 |
Mycobacterium leprae | PROBABLE DIAMINOPIMELATE DECARBOXYLASE LYSA (DAP DECARBOXYLASE) | 0.0047 | 0 | 0.5 |
Mycobacterium ulcerans | diaminopimelate decarboxylase LysA | 0.0122 | 0.3743 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0105 | 0.2914 | 0.7786 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0105 | 0.2914 | 0.7793 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0105 | 0.2914 | 0.7283 |
Chlamydia trachomatis | sulfite reductase | 0.0065 | 0.09 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0105 | 0.2914 | 0.7283 |
Trichomonas vaginalis | ornithine decarboxylase, putative | 0.0122 | 0.3743 | 1 |
Toxoplasma gondii | diaminopimelate decarboxylase | 0.0122 | 0.3743 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0247 | 1 | 1 |
Echinococcus multilocularis | arachidonate 5 lipoxygenase | 0.012 | 0.3665 | 1 |
Loa Loa (eye worm) | pyridoxal-dependent decarboxylase | 0.0122 | 0.3743 | 0.3124 |
Loa Loa (eye worm) | hypothetical protein | 0.0105 | 0.2914 | 0.2213 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0105 | 0.2914 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0105 | 0.2914 | 0.2213 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0105 | 0.2914 | 0.4194 |
Trichomonas vaginalis | ornithine decarboxylase, putative | 0.0122 | 0.3743 | 1 |
Trichomonas vaginalis | diaminopimelate decarboxylase, putative | 0.0122 | 0.3743 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0105 | 0.2914 | 0.5 |
Onchocerca volvulus | 0.0122 | 0.3743 | 0.5 | |
Leishmania major | ornithine decarboxylase, putative | 0.0122 | 0.3743 | 1 |
Leishmania major | p450 reductase, putative | 0.0105 | 0.2914 | 0.4194 |
Trichomonas vaginalis | diaminopimelate decarboxylase, putative | 0.0122 | 0.3743 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0105 | 0.2914 | 0.4194 |
Brugia malayi | flavodoxin family protein | 0.0105 | 0.2914 | 0.2213 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0105 | 0.2914 | 0.7283 |
Mycobacterium tuberculosis | Diaminopimelate decarboxylase LysA (DAP decarboxylase) | 0.0122 | 0.3743 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0065 | 0.09 | 0.1876 |
Trichomonas vaginalis | pyridoxal-dependent decarboxylase, putative | 0.0122 | 0.3743 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0053 | 0.0301 | 0.0118 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0093 | 0.2315 | 0.6186 |
Brugia malayi | FAD binding domain containing protein | 0.0105 | 0.2914 | 0.2213 |
Brugia malayi | Pyridoxal-dependent decarboxylase, pyridoxal binding domain containing protein | 0.0122 | 0.3743 | 0.3124 |
Schistosoma mansoni | lipoxygenase | 0.012 | 0.3665 | 1 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0247 | 1 | 1 |
Schistosoma mansoni | lipoxygenase | 0.0084 | 0.1855 | 0.4681 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.